Spero Therapeutics, Inc.
SPRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $106 | $162 | $40 | $56 |
| - Cash | $49 | $31 | $49 | $53 |
| + Debt | $3 | $4 | $4 | $4 |
| Enterprise Value | $61 | $135 | -$5 | $7 |
| Revenue | $3 | $12 | $6 | $15 |
| % Growth | -74.2% | 100.9% | -61% | – |
| Gross Profit | $3 | $12 | -$8 | -$80 |
| % Margin | 100% | 100% | -131.6% | -529% |
| EBITDA | -$7 | -$2 | -$15 | -$21 |
| % Margin | -242.2% | -20% | -247.8% | -138.6% |
| Net Income | -$7 | -$2 | -$14 | -$21 |
| % Margin | -242.2% | -14.4% | -236.1% | -138.8% |
| EPS Diluted | -0.13 | -0.03 | -0.25 | -0.39 |
| % Growth | -329% | 87.9% | 35.9% | – |
| Operating Cash Flow | $17 | -$18 | -$4 | -$23 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $17 | -$18 | -$4 | -$23 |